Shopping Cart 0
Cart Subtotal
USD 0

Curie Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Curie Institute is a cancer research foundation that operates cancer research institutes and hospitals and concentrates on the developing new treatments for cancer. The foundation carries out research in the areas of immunology, pharmachemistry, bioinformatics and systems biology, cell biology and developmental biology, among others. It provides services in the area such as genetics and carcinogenesis, cell and tissue imaging, and others. It offers care, research and training services for detecting, treating and monitoring cancer. Curie Institute provides services in anesthesia, medicine, pediatrics, surgery, tumor biology, intensive care, pain and medical imaging, among others. The foundation offers masters, PhD and postdoctoral fellowship programmes, and other courses. Curie Institute is headquartered in Paris, France.

Curie Institute-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Curie Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Curie Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Curie Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Curie Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Curie Institute, Medical Devices Deals, 2012 to YTD 2018 9

Curie Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Curie Institute, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Institut Curie Enters into Agreement with Pierre Fabre 12

Roche and Institut Curie Enter into Agreement 13

Institut Curie Enters into Collaboration Agreement with Epidemium 14

Ignyta and Institut Curie Enter into Partnership 15

Bristol-Myers Squibb Enters into Co-Development Agreement with Institut Curie 16

Celyad Enters into Partnership with Institut Curie 17

Curie-Cancer Extends Co-Development Agreement with GamaMabs Pharma 18

Curie-Cancer Partners with Inventiva 19

Institut Curie Extends Research Agreement with Servier 20

Curie-Cancer Enters into Co-Development Agreement with GamaMabs Pharma 21

Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 22

Curie-Cancer And GenoSplice Form Bioinformatics Partnership For Cancer Genomics 23

Curie-Cancer Enters Into Research Agreement With Harmonic Pharma 24

Licensing Agreements 25

Stimunity Enters into Licensing Agreement with Inserm Transfert and Institut Curie 25

Theravectys Enters into Licensing Agreement with Institut Curie 26

Abbott Molecular Enters into Licensing Agreement with Institut Curie 27

PEP-Therapy Enters into Agreement with Inserm Transfert, Institut Curie and Pierre and Marie 28

Meiogenix Enters Into Licensing Agreement With Curie-Cancer And Institut National de la Recherche Agronomique 29

Floralis Enters into Licensing Agreement with Ecrins Therapeutics 30

Curie Institute-Key Competitors 31

Curie Institute-Key Employees 32

Curie Institute-Locations And Subsidiaries 33

Head Office 33

Recent Developments 34

Strategy And Business Planning 34

Sep 17, 2018: Institut Curie announces creation of Honing Biosciences 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35


List Of Figure

List of Figures

Curie Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Curie Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Curie Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Curie Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Curie Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Curie Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Curie Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Curie Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Curie Institute, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Curie Institute, Pharmaceuticals & Healthcare, Key Facts 2

Curie Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Curie Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Curie Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Curie Institute, Deals By Therapy Area, 2012 to YTD 2018 8

Curie Institute, Medical Devices Deals, 2012 to YTD 2018 9

Curie Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Institut Curie Enters into Agreement with Pierre Fabre 12

Roche and Institut Curie Enter into Agreement 13

Institut Curie Enters into Collaboration Agreement with Epidemium 14

Ignyta and Institut Curie Enter into Partnership 15

Bristol-Myers Squibb Enters into Co-Development Agreement with Institut Curie 16

Celyad Enters into Partnership with Institut Curie 17

Curie-Cancer Extends Co-Development Agreement with GamaMabs Pharma 18

Curie-Cancer Partners with Inventiva 19

Institut Curie Extends Research Agreement with Servier 20

Curie-Cancer Enters into Co-Development Agreement with GamaMabs Pharma 21

Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 22

Curie-Cancer And GenoSplice Form Bioinformatics Partnership For Cancer Genomics 23

Curie-Cancer Enters Into Research Agreement With Harmonic Pharma 24

Stimunity Enters into Licensing Agreement with Inserm Transfert and Institut Curie 25

Theravectys Enters into Licensing Agreement with Institut Curie 26

Abbott Molecular Enters into Licensing Agreement with Institut Curie 27

PEP-Therapy Enters into Agreement with Inserm Transfert, Institut Curie and Pierre and Marie 28

Meiogenix Enters Into Licensing Agreement With Curie-Cancer And Institut National de la Recherche Agronomique 29

Floralis Enters into Licensing Agreement with Ecrins Therapeutics 30

Curie Institute, Key Competitors 31

Curie Institute, Key Employees 32

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Curie Institute, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.